Overexpression of Galectin-3 in Chronic Lymphocytic Leukemia Is Associated With 17p Deletion: A Short Report

Anticancer Res. 2019 Jun;39(6):2805-2810. doi: 10.21873/anticanres.13408.

Abstract

Background/aim: Galectins belong to the family of galactose-binding proteins known to play an important role in the processes of cell proliferation, differentiation, migration and neoplastic progression. Herein, we studied the expression of galectin-3 (Gal-3) in chronic lymphocytic leukemia (CLL).

Materials and methods: The expression of Gal-3 was analyzed by means of multiparametric flow cytometry in normal and pathological B-cells from peripheral blood and bone marrow samples of 67 patients with CLL.

Results: Pathological B-cells expressed significantly higher levels of cytoplasmic Gal-3 than normal B-cells. Moreover, overexpression of cytoplasmic Gal-3 was observed in the prognostically poorest subgroup of CLL patients, namely those with 17p deletion.

Conclusion: Our results indicate a possible role of galectin-3 in CLL pathophysiology and its potential value as a prognostic marker and therapeutic target.

Keywords: 17p deletion; B-cells; Galectin-3; chronic lymphocytic leukemia; cytogenetics; flow cytometry.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor / genetics
  • Blood Proteins
  • Chromosome Deletion*
  • Chromosomes, Human, Pair 17 / genetics*
  • Cytoplasm / metabolism
  • Female
  • Galectin 3 / genetics*
  • Galectins
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / genetics*
  • Male
  • Middle Aged
  • Prognosis
  • Up-Regulation*

Substances

  • Biomarkers, Tumor
  • Blood Proteins
  • Galectin 3
  • Galectins
  • LGALS3 protein, human